Summary

Global AI in drug discovery market is expected to grow at a robust CAGR during the forecast period. The global AI in drug discovery market is driven by the growing need to shorten the drug discovery process in order to get drugs faster for treating various chronic and viral diseases. Additionally, AI helps in understanding the mechanism of disease, establishing biomarkers and generating data or models for the drug discovery process and thereby expected to propel the market over the next few years. Furthermore, increasing R&D activities and software launches by the major market players is expected to spur the market through 2025.

The global AI in drug discovery market is segmented based on component, technology, drug type, application, diseases, end user, company and region. Based on component, the market can be bifurcated into software and services. The software segment is expected to dominate the market during forecast period owing to the continuous software advancements that caters to the requirements of healthcare industry. Based on application, the market can be fragmented into target identification, in silico drug design, drug development, big data analytics, prediction of study risks, patient matching and others. The drug development segment is expected to witness significant growth over the next few years. This can be ascribed to the role of AI in designing drugs, setting up preclinical experiments and running clinical trials. Based on disease, the market can be grouped into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, others. The immune-oncology segment is expected to register the highest CAGR during the forecast years on account of the growing demand for effective cancer treatment drugs.

Regionally, the AI in drug discovery market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these, North America is expected to dominate the overall AI in drug discovery market owing to the early adoption of technologies and well developed healthcare infrastructure in the region.

Major players operating in the global AI in drug discovery market include IBM Corporation, Microsoft Corporation, Google Inc., NVIDIA Corporation, Pfizer, Merck, GSK, Novartis, AstraZeneca, Abbvie, Elli Lilly, Atomwise, Inc, Deep Genomics, Cloud Pharmaceuticals, Exscientia, Cyclica, Numerate, Envisagenics, OWKIN, Inc., Verge Genomics and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments. For instance, in 2016, IBM along with Pfizer launched IBM Watson, a cloud based platform for drug discovery. IBM Watson allows users to analyze personal medical data such as medical reports and helps the researchers in identifying relationship between potential medical data using dynamic visualizations.
Years considered for this report:
Historical Years: 2015-2018
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2021–2025
Objective of the Study:
• To analyze and estimate the market size of global AI in drug discovery market from 2015 to 2018.
• To estimate and forecast the market size of global AI in drug discovery market from 2019 to 2025 and growth rate until 2025.
• To classify and forecast global AI in drug discovery market based on component, technology, drug type, application, diseases, end user, company and regional distribution.
• To identify dominant region or segment in the global AI in drug discovery market.
• To identify drivers and challenges for global AI in drug discovery market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global AI in drug discovery market.
• To identify and analyze the profile of leading players operating in global AI in drug discovery market.
• To identify key sustainable strategies adopted by market players in global AI in drug discovery market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the service providers, distribution channels and presence of all major players across the globe.
TechSci Research calculated the market size of global AI in drug discovery market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• AI in drug discovery service providers, vendors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to AI in drug discovery
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as service providers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global AI in drug discovery market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global AI in Drug Discovery Market, By Component:
o Software
o Services
• Global AI in Drug Discovery Market, By Technology:
o Machine Learning
o Deep Learning
o Others
• Global AI in Drug Discovery Market, By Drug Type:
o Small Molecule
o Large Molecule
• Global AI in Drug Discovery Market, By Application:
o Target Identification
o In Silico Drug Design
o Drug Development
o Big Data Analytics
o Prediction Of Study Risks
o Patient Matching
o Others
• Global AI in Drug Discovery Market, By Diseases:
o Immuno-oncology
o Neurodegenerative Diseases
o Cardiovascular Diseases
o Metabolic Diseases
o Others
• Global AI in Drug Discovery Market, By End User:
o Pharmaceutical & Biotechnology Companies
o Contract Research Organizations
o Research Centers and Academic & Government Institutes
• Global AI in Drug Discovery Market, By Region:
o North America
 United States
 Canada
 Mexico
o Europe
 Germany
 France
 United Kingdom
 Italy
 Spain
o Asia-Pacific
 China
 Japan
 India
 South Korea
 Australia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 Kuwait
o South America
 Brazil
 Argentina
 Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global AI in drug discovery market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
5. Global AI in Drug Discovery Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Component (Software v/s Services)
5.2.2. By Technology (Machine Learning, Deep Learning, Others)
5.2.3. By Drug Type (Small Molecule v/s Large Molecule)
5.2.4. By Application (Target Identification, In Silico Drug Design, Drug Development, Big Data Analytics, Prediction Of Study Risks, Patient Matching, Others)
5.2.5. By Diseases (Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Others)
5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Research Centers and Academic & Government Institutes)
5.2.7. By Company (2019)
5.2.8. By Region
5.3. Product Market Map
6. Asia-Pacific AI in Drug Discovery Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component
6.2.2. By Technology
6.2.3. By Drug Type
6.2.4. By Application
6.2.5. By Diseases
6.2.6. By End User
6.2.7. By Country
6.3. Asia-Pacific: Country Analysis
6.3.1. China AI in Drug Discovery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Component
6.3.1.2.2. By Technology
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Application
6.3.1.2.5. By Diseases
6.3.1.2.6. By End User
6.3.2. India AI in Drug Discovery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Component
6.3.2.2.2. By Technology
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Application
6.3.2.2.5. By Diseases
6.3.2.2.6. By End User
6.3.3. Australia AI in Drug Discovery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Component
6.3.3.2.2. By Technology
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Application
6.3.3.2.5. By Diseases
6.3.3.2.6. By End User
6.3.4. Japan AI in Drug Discovery Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Component
6.3.4.2.2. By Technology
6.3.4.2.3. By Drug Type
6.3.4.2.4. By Application
6.3.4.2.5. By Diseases
6.3.4.2.6. By End User
6.3.5. South Korea AI in Drug Discovery Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Component
6.3.5.2.2. By Technology
6.3.5.2.3. By Drug Type
6.3.5.2.4. By Application
6.3.5.2.5. By Diseases
6.3.5.2.6. By End User
7. Europe AI in Drug Discovery Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component
7.2.2. By Technology
7.2.3. By Drug Type
7.2.4. By Application
7.2.5. By Diseases
7.2.6. By End User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. France AI in Drug Discovery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Technology
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Application
7.3.1.2.5. By Diseases
7.3.1.2.6. By End User
7.3.2. Germany AI in Drug Discovery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Technology
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Application
7.3.2.2.5. By Diseases
7.3.2.2.6. By End User
7.3.3. United Kingdom AI in Drug Discovery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Technology
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Application
7.3.3.2.5. By Diseases
7.3.3.2.6. By End User
7.3.4. Italy AI in Drug Discovery Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Component
7.3.4.2.2. By Technology
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Application
7.3.4.2.5. By Diseases
7.3.4.2.6. By End User
7.3.5. Spain AI in Drug Discovery Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Component
7.3.5.2.2. By Technology
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Application
7.3.5.2.5. By Diseases
7.3.5.2.6. By End User
8. North America AI in Drug Discovery Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component
8.2.2. By Technology
8.2.3. By Drug Type
8.2.4. By Application
8.2.5. By Diseases
8.2.6. By End User
8.2.7. By Country
8.3. North America: Country Analysis
8.3.1. United States AI in Drug Discovery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technology
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Application
8.3.1.2.5. By Diseases
8.3.1.2.6. By End User
8.3.2. Mexico AI in Drug Discovery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technology
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Application
8.3.2.2.5. By Diseases
8.3.2.2.6. By End User
8.3.3. Canada AI in Drug Discovery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technology
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Application
8.3.3.2.5. By Diseases
8.3.3.2.6. By End User
9. South America AI in Drug Discovery Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component
9.2.2. By Technology
9.2.3. By Drug Type
9.2.4. By Application
9.2.5. By Diseases
9.2.6. By End User
9.2.7. By Country
9.3. South America: Country Analysis
9.3.1. Brazil AI in Drug Discovery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technology
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Application
9.3.1.2.5. By Diseases
9.3.1.2.6. By End User
9.3.2. Argentina AI in Drug Discovery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technology
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Application
9.3.2.2.5. By Diseases
9.3.2.2.6. By End User
9.3.3. Colombia AI in Drug Discovery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technology
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Application
9.3.3.2.5. By Diseases
9.3.3.2.6. By End User
10. Middle East and Africa AI in Drug Discovery Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component
10.2.2. By Technology
10.2.3. By Drug Type
10.2.4. By Application
10.2.5. By Diseases
10.2.6. By End User
10.2.7. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa AI in Drug Discovery Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technology
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Application
10.3.1.2.5. By Diseases
10.3.1.2.6. By End User
10.3.2. Saudi Arabia AI in Drug Discovery Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technology
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Application
10.3.2.2.5. By Diseases
10.3.2.2.6. By End User
10.3.3. UAE AI in Drug Discovery Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technology
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Application
10.3.3.2.5. By Diseases
10.3.3.2.6. By End User
10.3.4. Kuwait AI in Drug Discovery Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Component
10.3.4.2.2. By Technology
10.3.4.2.3. By Drug Type
10.3.4.2.4. By Application
10.3.4.2.5. By Diseases
10.3.4.2.6. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
13. Competitive Landscape
13.1. IBM Corporation
13.2. Microsoft Corporation
13.3. Google Inc.
13.4. NVIDIA Corporation
13.5. Pfizer
13.6. Merck
13.7. GSK
13.8. Novartis
13.9. AstraZeneca
13.10. Abbvie
13.11. Elli Lilly
13.12. Atomwise, Inc
13.13. Deep Genomics
13.14. Cloud Pharmaceuticals
13.15. Exscientia
13.16. Cyclica
13.17. Numerate
13.18. Envisagenics
13.19. OWKIN, Inc.
13.20. Verge Genomics
14. Strategic Recommendations
15. About Us & Disclaimer